Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1Phase 2 1

Status

Completed 8Recruiting 6Unknown 2Terminated 2Withdrawn 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Hematologic Neoplasms 1

Interventions

Cisplatin 22Carboplatin 15Radiotherapy 13Paclitaxel 11Gemcitabine 10Rituximab 9Fluorouracil 9Drug Therapy 6Dexamethasone 5Cyclophosphamide 5Capecitabine 5Bevacizumab 5Vinorelbine 4Pemetrexed 4Nivolumab 4Methotrexate 4Etoposide 4Docetaxel 4Bendamustine Hydrochloride 4spartalizumab 3pertuzumab 3pembrolizumab 3fludarabine 3Vincristine 3Trastuzumab 3Surgical Procedures, Operative 3Standard of Care 3Prednisone 3Oxaliplatin 3Lenalidomide 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Withdrawn × Olanzapine × Clear all
NCT05403580 2024-05-06

Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Patients With Advanced Cancer

Mayo Clinic

Phase 3 Withdrawn
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡